Trial NCT01399593

View at ClinicalTrials.gov 
Org. Study IDs: C10-001
Secondary IDs: 2010-019630-28 BB-IND: 100,003

Last trial update was posted on 2017-10-03

MeSH Interventions

Eculizumab

MeSH Conditions


Other Conditions

Antibody Mediated Rejection

Stopping Reasons

Did not achieve statistical significance for primary endpoint

Limitations And Caveats

Data interpretation confounded by open-label study with potential reporting bias, unequal exposure to randomized prevention therapy between groups, some patients in SOC arm received eculizumab for treatment of AMR, all patients immunosuppressed.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID